Business & Finance
Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
Key Points
Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials Bambusa Therapeutics Inc. filed for a initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders. The Boston-based company is working on long-acting bispecific antibodies to treat unmet needs in the more than $150 billion-a-year global immunology and inflammation market, encompassing skin, respiratory, gastroenterology and autoimmune diseases, according to a filing Friday with the US...
Bambusa Therapeutics Files for IPO to Fund Eczema Drug Trials
Bambusa Therapeutics Inc. filed for a initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders.
The Boston-based company is working on long-acting bispecific antibodies to treat unmet needs in the more than $150 billion-a-year global immunology and inflammation market, encompassing skin, respiratory, gastroenterology and autoimmune diseases, according to a filing Friday with the US Securities and Exchange Commission.